EcoDrugPlus

Checkpoint Kinase 1

Ensembl ID : ENSTNIG00000009981
Gene Symbol: CHEK1
2 Cross references
177 Possible Orthologues:

Checkpoint Kinase 2

Ensembl ID : ENSTNIG00000004423
Gene Symbol: CHEK2
2 Cross references
204 Possible Orthologues:

Chemokine (C-C Motif) Receptor 9a

Ensembl ID : ENSTNIG00000003072
Gene Symbol: CCR9A
2 Cross references
188 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 4a

Ensembl ID : ENSTNIG00000000918
Gene Symbol: CXCR4A
3 Cross references
201 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSTNIG00000012993
Gene Symbol: CCKAR
3 Cross references
200 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSTNIG00000013929
Gene Symbol: CCKBR
3 Cross references
191 Possible Orthologues:

Cholecystokinin B Receptor A

Ensembl ID : ENSTNIG00000010350
Gene Symbol: CCKBRA
2 Cross references
193 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSTNIG00000005239
Gene Symbol: CETP
2 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSTNIG00000017024
Gene Symbol: CHRM3
2 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSTNIG00000004464
Gene Symbol: CHRM3
2 Cross references
185 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSTNIG00000011964
Gene Symbol: CHRNA3
2 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSTNIG00000018333
Gene Symbol: CHRNB2
2 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).